featured
2023 Top Story in Oncology: CAR T-Cell Therapy (Cilta-Cel) vs Standard of Care for Early Relapse Multiple Myeloma—The CARTITUDE-4 Study
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
- San-Miguel J, Dhakal B, Yong K, et al. Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma. N Engl J Med. 2023;389(4):335-347.
- Rodriguez-Otero P, Ailawadhi S, Arnulf B, et al. Ide-cel or Standard Regimens in Relapsed and Refractory Multiple Myeloma. N Engl J Med. 2023;388(11):1002-1014.
Disclosure statements are available on the authors' profiles: